RecruitingNCT07282470

Epigenetic Profiling and Liquid Biopsy: Perspectives for Personalized Medicine in Meningioma Patients - MIND

Epigenetic Profiling and Liquid Biopsy: Perspectives for Personalized Medicine in Meningioma Patients

Sponsor

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

Enrollment

210 participants

Start Date

Sep 25, 2024

Study Type

OBSERVATIONAL

Conditions

Meningioma Meningioma of Brain

Summary

Meningiomas are the most common primary intracranial tumors. Current treatment relies on surgical resection and radiotherapy, but molecular predictors for recurrence are lacking. This study aims to investigate epigenetic features, specifically histone post-translational modifications (PTMs) and DNA methylation, to stratify patients. The study involves a retrospective cohort to define an epigenetic signature and a prospective cohort to validate it in tissues and liquid biopsies (plasma/EVs).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is examining tumor samples and blood (liquid biopsy) from meningioma patients to find genetic and biological markers that predict whether the tumor will come back after surgery. **You may be eligible if...** - You are 18 or older - You have been newly diagnosed with a single meningioma (a usually benign brain tumor) on the outer surface of the brain - Your surgeon was able to completely remove the tumor (Simpson grade 1–3) - For the retrospective (past records) part: your surgery was between 2007 and 2016, and tissue samples from that surgery are still available - For the prospective (going forward) part: this is your first meningioma diagnosis and treatment **You may NOT be eligible if...** - You have a genetic syndrome that predisposes you to tumors - You have meningiomas spread across multiple areas of the brain (diffuse meningeal meningiomatosis) - You received experimental treatment before surgery - You have a history of another cancer (prospective group only) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.